Qi-Jing Li is a prominent inventor based in Mountain View, CA (US). He has made significant contributions to the field of immunology, particularly in understanding T cell signaling and sensitivity to antigens. With a total of 4 patents, his work has implications for therapeutic strategies in immune-related diseases.

Latest Patents

One of Qi-Jing Li's latest patents focuses on the modulation of T cell signaling threshold and T cell sensitivity to antigens. This research highlights the role of microRNAs (miRNAs), specifically miR-181a, in enhancing T cell activation. Increased expression of miR-181a in mature T cells leads to a marked increase in their sensitivity to peptide antigens. Furthermore, T cell blasts with elevated miR-181a expression become reactive to antagonists. The modulation of antigen discrimination is achieved by dampening the expression of negative regulators in the T cell receptor (TCR) signaling pathway, which results in a reduced TCR signaling threshold. This enhancement quantitatively and qualitatively improves T cell sensitivity to antigens.

Career Highlights

Qi-Jing Li is affiliated with Leland Stanford Junior University, where he continues to advance research in immunology. His innovative approaches have garnered attention in the scientific community, contributing to a deeper understanding of T cell biology.

Collaborations

Some of his notable coworkers include Chang-Zheng Chen and Mark M Davis, who have collaborated with him on various research projects.

Conclusion

Qi-Jing Li's work in T cell signaling represents a significant advancement in immunological research. His patents and collaborations reflect his commitment to enhancing our understanding of immune responses.